Aurelia Butler

A research team at the University of Washington has developed a wearable device to detect and reverse an opioid overdose. The device, worn on the stomach like an insulin pump, senses when a person stops breathing and moving, and injects naloxone, a lifesaving antidote that can restore respiration.
The results demonstrate the proof-of-concept of a wearable naloxone injector system, according to the paper published Nov. 22 in Scientific Reports.
“The opioid epidemic has become worse during the pandemic and has continued to be a major public health crisis,” said lead author Justin Chan, a UW doctoral student in the Paul G. Allen School of Computer Science & Engineering. “We have created algorithms that run on a wearable injector to detect when the wearer stops breathing and automatically inject naloxone.”
Co-author Jacob Sunshine, an associate professor of anesthesiology and pain medicine at the UW School of Medicine, said one of the unique aspects of opioid overdoses is that naloxone, a benign drug, is highly effective and can save lives if it can be administered in a timely fashion.
The UW team is looking to make these devices widely available, which would first require approval by the U.S. Food and Drug Administration. The FDA is currently working to accelerate efforts to address this critical public health problem and has recently published special guidance on emergency-use injectors.
In a multiyear collaboration, the UW investigators worked on the prototype with West Pharmaceutical Services of Exton, Penn, which developed a wearable subcutaneous injector that safely administers medications. More

A team of University of Arizona researchers has developed an ultra-thin wireless device that grows to the surface of bone and could someday help physicians monitor bone health and healing over long periods. The devices, called osseosurface electronics, are described in a paper published Thursday in Nature Communications.
“As a surgeon, I am most excited about using measurements collected with osseosurface electronics to someday provide my patients with individualized orthopedic care — with the goal of accelerating rehabilitation and maximizing function after traumatic injuries,” said study co-senior author Dr. David Margolis, an assistant professor of orthopedic surgery in the UArizona College of Medicine — Tucson and orthopedic surgeon at Banner — University Medical Center Tucson.
Fragility fractures associated with conditions like osteoporosis account for more days spent in the hospital than heart attacks, breast cancer or prostate cancer. Although not yet tested or approved for use in humans, the wireless bone devices could one day be used not only to monitor health, but to improve it, said study co-senior author Philipp Gutruf, an assistant professor of biomedical engineering and Craig M. Berge faculty fellow in the College of Engineering.
“Being able to monitor the health of the musculoskeletal system is super important,” said Gutruf, who is also a member of the university’s BIO5 Institute. “With this interface, you basically have a computer on the bone. This technology platform allows us to create investigative tools for scientists to discover how the musculoskeletal system works and to use the information gathered to benefit recovery and therapy.”
Because muscles are so close to bones and move so frequently, it is important that the device be thin enough to avoid irritating surrounding tissue or becoming dislodged, Gutruf explained.
“The device’s thin structure, roughly as thick as a sheet of paper, means it can conform to the curvature of the bone, forming a tight interface,” said Alex Burton, a doctoral student in biomedical engineering and co-first author of the study. “They also do not need a battery. This is possible using a power casting and communication method called near-field communication, or NFC, which is also used in smartphones for contactless pay.”
Ceramic Adhesive Grows to Bone
The outer layers of bones shed and renew just like the outer layers of skin. So, if a traditional adhesive was used to attach something to the bone, it would fall off after just a few months. To address this challenge, study co-author and BIO5 Institute member John Szivek — a professor of orthopedic surgery and biomedical engineering — developed an adhesive that contains calcium particles with an atomic structure similar to bone cells, which is used as to secure osseosurface electronics to the bone.
“The bone basically thinks the device is part of it, and grows to the sensor itself,” Gutruf said. “This allows it to form a permanent bond to the bone and take measurements over long periods of time.”
For instance, a doctor could attach the device to a broken or fractured bone to monitor the healing process. This could be particularly helpful in patients with conditions such as osteoporosis, since they frequently suffer refractures. Knowing how quickly and how well the bone is healing could also inform clinical treatment decisions, such as when to remove temporary hardware like plates, rods or screws.
Some patients are prescribed drugs designed to speed up bone healing or improve bone density, but these prescriptions can have side effects. Close bone monitoring would allow physicians to make more informed decisions about drug dosage levels.
Story Source:
Materials provided by University of Arizona College of Engineering. Original written by Emily Dieckman. Note: Content may be edited for style and length. More

Special ferroelectric features offer promise for microelectronics and energy applications.
When a magician suddenly pulls a tablecloth off a table laden with plates and glasses, there is a moment of suspense as the audience wonders if the stage will soon be littered with broken glass. Until now, an analogous dilemma had faced scientists working with special electrical bubbles to create the next generation of flexible microelectronic and energy storage devices.
Scientists at the U.S. Department of Energy’s (DOE) Argonne National Laboratory have discovered a new way to do an atomic-scale version of the tablecloth trick by peeling off heterostructure thin films containing electrical bubbles from a particular underlying material, or substrate, while keeping them fully intact. The discovery may bring us one step closer to a host of applications that rely upon these unusual and brittle structures.
“The bubbles are very fragile and initially need particular underlying materials, called substrates, and specific conditions in order to grow films with them in,” said Argonne materials scientist Saidur Bakaul. “There are many materials of interest to us for which these bubbles could be extremely useful, like plastics. However, we haven’t been able to grow them directly on these materials. Our research is the initial step to make bubbles possible there.”
The electric bubbles are found in a three-layer ultrathin structure with alternating electrical properties: ferroelectric, then dielectric, then ferroelectric again. The bubbles in this multilayer structure are made out of specially ordered dipoles, or twinned electric charges. The orientation of these dipoles is based on the local strain in the material and charges on the surface which cause the dipoles to seek out their relative lowest energy state. Eventually, the electric bubbles (bubble domains) form but only when certain conditions are met. They are also easily distorted by even small forces.
In the experiment, Bakaul’s colleagues at University of New South Wales first grew the bubbles in an ultrathin heterostructure film on a strontium titanate substrate — one of the easiest materials on which to create them. Then, Bakaul faced the challenge of removing the heterostructure from the substrate while retaining the bubbles. “You can think of it like trying to remove a house from its foundation,” he said. “Normally, you would think that the house would collapse, but we found that it retained all of its properties.”
Bubble domains are tiny. They’re only about 4 nanometers in radius — just as wide as a human DNA strand. Therefore, they are difficult to see. In Argonne’s Materials Science division, advanced scanning probe microscopy techniques with Fourier transform analysis allow scientists to not only see them but also quantify their properties in the freestanding films. More

The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In individuals carrying mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes an ion channel controlling the flow of ions and water in and out of cells, the mucus in airways and other passageways, which normally is thin and slippery, becomes sticky and thick — thus instead of acting as a lubricant, it becomes a congestant.
Advances in patient screenings and breakthrough therapies allow CF patients now to live into their mid- to late 30s or 40s, sometimes even longer. However, even the ~90% of patients (dependent on continent) with the most common CFTR mutation, called ?F508, who can be treated with available drugs, are still plagued by bacteria settling in their mucus, which causes inflammation in their lungs. The repeated bouts of infection and inflammation, as well as a chronic lower-grade inflammation between infections, gradually weakens and scars patients’ airways, which eventually causes their respiratory systems to fail. For the remaining ~10% of patients with various other CFTR mutations, no targeted treatments even exist yet. A major barrier to developing new and urgently needed treatments is the lack of human in vitro models that recapitulate the CF disease’s pathology.
Now, a multidisciplinary research team at Harvard’s Wyss Institute for Biologically Inspired Engineering led by Wyss Founding Director Donald Ingber, M.D., Ph.D. and supported by a grant from the Cystic Fibrosis Foundation, have developed a microfluidic Organ Chip device the size of a USB memory stick that recapitulates key pathological hallmarks from CF patients more accurately than other in vitro systems have so far. The model replicates CF-specific changes in multiple hallmarks of the disease, including in the airway’s mucus layer, beating of mucus-transporting cilia, pathogen growth, inflammatory molecules, and the recruitment of white blood cells, providing a comprehensive preclinical human model in which to investigate new CF therapies. The findings are published in the Journal of Cystic Fibrosis.
“Now that we are able to accurately model CF pathology, including microbiome and inflammatory responses, in human Airway Chips, we have a way to attack challenges that are important to CF patients,” said Ingber. “The bundled capabilities of this advanced in vitro model can help accelerate the search for drugs that may dampen the exaggerated immune response in patients, treat them with more personalized therapies and, help solve problems that CF patients face every day which cannot be addressed by existing treatments.” Ingber also is faculty lead of the Wyss’ Bioinspired Therapeutics & Diagnostics Platform, as well as the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
To model and compare the microstructure and function of vascularized CF airways, the authors grew lung airway cells obtained from human CF patients or healthy individuals in one of two parallel running hollow channels of a microfluidic device under air, recapitulating the lung’s air-transporting environment. In the second channel, which is separated from the first one by a porous membrane, they recreated a human blood vessel from human lung microvascular cells that was perfused with a blood substitute medium.
“This first microphysiological model of a CF airway closely mimics what we know from airways in CF patients. Maintaining the typical composition of all relevant cell types, it developed a thicker mucus layer, and its ciliated cells exhibit higher densities of cilia that beat at a higher frequency compared to Airway Chips created with airway cells from healthy individuals,” said co-first author and former Postdoctoral Fellow on Ingber’s team Ratnakar Potla, M.B.B.S., Ph.D. “Importantly, these pathological changes were accompanied by an enhanced inflammatory response in the modeled CF bronchial epithelium that is much like the one observed in CF patients.” Potla is now Senior Scientist of complex in vitrosystems at Genentech-Roche.
After culturing the Airway Chips for two weeks, the researchers measured the levels of pro- and anti-inflammatory factors flowing out of the Airway Chip’s vascular channel that are known to be involved in the inflammatory response in the lungs of CF patients. Among other changes, the level of the pro-inflammatory cytokine IL-8 was increased in CF chips compared to those in control Airway Chips. Interestingly, IL-8 is known for its ability to attract the type of white blood cells know as neutrophils that also drive inflammation in the lungs of CF patients.
When the researchers then actually flowed human neutrophils through the vascular channel of the CF Airway Chips, they observed that more of the immune cells spontaneously adhered to the surface of vascular cells, squeezed themselves through the vascular cell layer and porous membrane, and accumulated in the airway epithelial cell layer of the air channel — recapitulating a process known as “transmigration.”
But the CF-mimicking airway tissue not only stimulated immune cell recruitment, it also supported the growth of the bacterium, Pseudomonas aeruginosa, which is present in the microbiome of normal lung but can grow out of control and cause lung infections in human CF patients. Twenty-four hours after they introduced a fluorescently labeled version of P. aeruginosa into the airway channel of chips created with bronchial epithelial cells from CF patients, the team detected higher numbers of the pathogen in CF-specific mucus than in mucus in healthy Airway Chips. As a consequence, the levels of pro-inflammatory cytokines were further increased, thus replicating the infection-inflammation cycle seen in CF patients.
As next steps, the team will further personalize their CF Lung Airway Chip by generating versions in which bronchial epithelial, vascular endothelial, and immune cells all are obtained from the same patient. “For this proof-of-concept study, we have only used CF-specific bronchial airway cells from patients carrying the frequent ?F508 CFTR mutation. But different CFTR mutations may also affect the function of endothelial and immune cells and differ in their effects,” said co-first author Roberto Plebani, Ph.D. “By developing a panel of patient-specific Airway Chips using cells from patients with different mutations, and also by directly measuring the activity of differently compromised CFTR ion channels on-chip, drug responses and efficacies could be investigated in a highly personalized manner.” Plebani worked in Ingber’s lab as a visiting professor from the “G. d’Annnunzio” University of Chieti-Pescara in Italy, and spearheaded the project in Ingber’s group with Potla.
Other authors on the study were former and present members of Ingber’s team, including Mercy Soong, Haiqing Bai, Ph.D., Zohreh Izadifar, Ph.D., Amanda Jiang, Renee Travis, Chaitra Belgur, Alexandre Dinis, Mark Cartwright, Ph.D., Rachelle Prantil-Baun, Ph.D., Pawan Jolly, Ph.D., and Sarah Gilpin, Ph.D.; and Mario Romano, Ph.D. and Professor at the “G. d’Annnunzio” University of Chieti-Pescara in Italy. The study was funded by the Cystic Fibrosis Foundation, Harvard’s Wyss Institute for Biologically Inspired Engineering, and the Programme Operativo Nazionale Ricerca e Innovazione. More

Researchers at the USC Viterbi School of Engineering are using generative adversarial networks (GANs) — technology best known for creating deepfake videos and photorealistic human faces — to improve brain-computer interfaces for people with disabilities.
In a paper published in Nature Biomedical Engineering, the team successfully taught an AI to generate synthetic brain activity data. The data, specifically neural signals called spike trains, can be fed into machine-learning algorithms to improve the usability of brain-computer interfaces (BCI).
BCI systems work by analyzing a person’s brain signals and translating that neural activity into commands, allowing the user to control digital devices like computer cursors using only their thoughts. These devices can improve quality of life for people with motor dysfunction or paralysis, even those struggling with locked-in syndrome — when a person is fully conscious but unable to move or communicate.
Various forms of BCI are already available, from caps that measure brain signals to devices implanted in brain tissues. New use cases are being identified all the time, from neurorehabilitation to treating depression. But despite all of this promise, it has proved challenging to make these systems fast and robust enough for the real world.
Specifically, to make sense of their inputs, BCIs need huge amounts of neural data and long periods of training, calibration and learning.
“Getting enough data for the algorithms that power BCIs can be difficult, expensive, or even impossible if paralyzed individuals are not able to produce sufficiently robust brain signals,” said Laurent Itti, a computer science professor and study co-author. More

Companies in the digital technology industry are significantly underreporting the greenhouse gas emissions arising along the value chain of their products. Across a sample of 56 major tech companies surveyed in a study by the Technical University of Munich (TUM), more than half of these emissions were excluded from self-reporting in 2019. At approximately 390 megatons carbon dioxide equivalents, the omitted emissions are in the same ballpark as the carbon footprint of Australia. The research team has developed a method for spotting sources of error and calculating the omitted disclosures.
For policy makers and the private sector to set targets for reduced greenhouse gas emissions, it is important to know how much CO2 companies are actually emitting. However, there are no binding requirements for comprehensive accounting and full disclosure of these emissions. The Greenhouse Gas (GHG) Protocol is seen as a voluntary standard. It distinguishes three categories of emissions: Scope 1 refers to direct emissions from a company’s own activities, scope 2 refers to emissions from the production of purchased energy, and scope 3 to emissions from activities along the value chain, in other words all emissions from raw material extraction to the use of the end product. Scope 3 emissions often represent the majority of a company’s carbon footprint. Past studies have also shown that these emissions account for most reporting gaps. Until now, however, it was not possible to quantify these gaps or determine their causes.
Lena Klaaßen and Dr. Christian Stoll at the TUM School of Management of the Technical University of Munich (TUM) have developed a method for identifying reporting gaps for scope 3 emissions and used it in a case study to determine the carbon footprints of pre-selected digital technology companies. Their paper has now been published in the journal Nature Communications.
Companies publish inconsistent figures
Klaaßen and Stoll determined that many companies submit different greenhouse gas emission figures depending on where they are reporting them. They focused mainly on the companies’ own reports as compared with voluntary disclosures to the non-profit organization CDP. The annual survey of companies conducted by CDP is regarded as the most important collection of data based on the structure of the GHG Protocol. Most companies disclose lower emissions in their own reports than in the CDP survey. This could be partly due to the fact that the CDP report is intended mainly for investors, while corporate reports are addressed to the general public.
In addition, CDP leaves it up to the reporting companies to choose which of the 15 GHG Protocol categories — ranging from business travel to waste disposal — are relevant to them. The studies show that this discretionary freedom results in some companies ignoring certain categories or not fully reporting the related emissions. Most companies have reporting gaps simply because they do not receive emissions data from all suppliers and do not fill the gaps with secondary data. More